Advertisement
Investigations on platelet/aneurysm interactions lead to $2.6 million NIH grant
FDA-designated breakthrough device offers first treatment option for severe TR and right HF
Longer-term confirmation of VALOR-HCM could yield a noninvasive therapy for severe obstructive HCM
Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
First U.S. implant at Cleveland Clinic signals another key shift away from transvenous leads
Essentials of the NIH study and how it compares with REPAIR MR
How to time the interventions, and how to manage anesthesia risks?
Innovative construct restores function after resection of softball-size chondrosarcoma
Interim report from large registry analysis compares favorably with pivotal trial
Both sexes, but especially women, stand to benefit from adding it to echo
Advertisement
Advertisement